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UbiquitinAll proteins in a cell continuously turn over, each at its own rate, contributing to a cell's development, differ-
entiation, or aging. Of course, unnecessary protein(s), or those synthesized in excess, that hamper cellular ho-
meostasis should be discarded rapidly. Furthermore, cells that have been subjected to various environmental
stresses, e.g., reactive oxygen species (ROS) and UV irradiation, may incur various types of protein damage,
which vitiate normal and homeostatic functions in the cell. Thereby, the prompt elimination of impaired pro-
teins is essential for cell viability. This housekeeping is accomplished by two major catabolic routes—
proteasomal digestion and autophagy. Strict maintenance of proteostasis is particularly important in
non-proliferative cells, especially neurons, and it is plausible that its failure leads to a number of the neuro-
degenerative diseases becoming prominent in the growing elderly population. This article is part of a Special
Issue entitled: Ubiquitin–Proteasome System. Guest Editors: Thomas Sommer and Dieter H. Wolf.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Proteins within a cell exist in a dynamic state, a balance between
synthesis and degradation, in which they turn over continuously
and perhaps stochastically. Indeed, the half-life of an individual pro-
tein ranges from minutes to months, a ~100,000-fold difference in
timespan. Proteolysis plays a central role in protein renewal, which
maintains the quality of proteins within the cell by destroying dys-
functional components. Two main sophisticated machineries—the
proteasome and autophagy—ensure proteolysis in eukaryotic cells
(Fig. 1). The proteasome, in collaboration with a reﬁned ubiquitin sys-
tem used for tagging target proteins, selectively degrades short-lived
regulatory proteins involved in the homeostatic control of the cell,
and abnormal proteins with aberrant structures, the excess accumula-
tion of which is usually harmful [1]. By contrast, the lysosomal proteoly-
sis guided by autophagy was initially thought to be a bulk protein
degradation system designed to non-selectively engulf cytoplasmic con-
stituents [2]. This latter route was seen to be a way for the cell to secure
nutrients while under starvation conditions. However, more recently,
surprising data have emerged demonstrating that autophagy, working
in tandem with ubiquitin, also contributes to a selective-degradation
process [3]. Accordingly, it is plausible that both proteasomal degra-
dation and autophagy are interrelated, using ubiquitin as a common
marker of proteins destined for degradation. Proteolysis is indispensable
to a wide variety of cellular events because it can impact biologicaltin–Proteasome System. Guest
+81 3 5316 3198.
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rights reserved.pathways irreversibly and in a spatiotemporal fashion. Proteolysis is
also integral to the elaborate quality-control mechanisms that ensure
steady-state levels of proteins (proteostasis), and it is becoming clear
that the failure of this control leads to a variety of neurodegenerative dis-
orders[4,5]. Indeed, protein misfolding, aggregation, and deposition are
common components of many neurodegenerative disorders including
Alzheimer's disease (AD) and Parkinson's disease (PD). The accumulation
of damaged or abnormally modiﬁed proteins may lead to perturbed cel-
lular functions and eventually to neuronal death, ultimately manifesting
as neurodegenerative disease.
This highlights the importance of the cellular surveillance system,
including the degradative pathways of the proteasome and autophagy.
Another important aspect of the cellular surveillance system is the mo-
lecular chaperones that refoldmisfolded proteins, helping to prevent cel-
lular toxicity. However, chaperone function is beyond the scope of this
review. Here, wewill focus on the consequences of neuronal proteasome
and autophagy deﬁciency leading to neurodegenerative disorder(s), and
will discuss several remaining issues that await further clariﬁcation.2. Ubiquitin and neurodegeneration
Ubiquitin tags proteins that are destined for degradation by a post-
translational modiﬁcation inwhich the ubiquitin is attached through an
isopeptide linkage between its terminal carboxyl-residue and a particu-
lar lysine-residue on the target protein. Since its discovery around 1980,
the biochemical and molecular mechanisms of ubiquitinylation have
been clariﬁed through extensive studies [6]. Today, it is established
that this posttranslational modiﬁcation is catalyzed through the co-
ordinated actions of the three types of enzymes: ubiquitin-activating
Cell 
Cycle
Trans- 
cription
Quality Control 
(Clearance) 
Signal  
Transduction
Immunity Starvation 
Response
Nutrients
Proteolysis
Diverse Arrays of Pathophysiology
Autophagosome
Lysosome
Isolated 
Membrane
Autolysosome
Autophagy-lysosome System
Ubiquitin
Substrate
Ubiquitin-Proteasome System 
Stress 
Response 
Fig. 1. Intracellular proteolysis is broadly classiﬁed into two distinct pathways consisting of the ubiquitin–proteasome and autophagy–lysosome, which are linked to a variety of
physiological and pathological mechanisms in eukaryotic cells.
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ubiquitin can itself be the target of another ubiquitin molecule, with
multiple rounds of repeated ubiquitinylation leading to the formation
of a so-called polyubiquitin chain. Ubiquitin possesses seven lysine
residues, including those at positions 48 and 63, and an N-terminal
methionine residue, all of which can nucleate polymer chains [7,8].
While the biological roles of polyubiquitin remain largely obscure, it has
been shown that the K48-linked ubiquitin-polymer chain is the primary
degradation signal for the proteasome, while the K63- and Met-linked
linear polyubiquitin chains do not typically function as proteasomal-
degradation signals. Instead, the latter participate in other processes,
e.g., transcriptional regulation, signal transduction, DNA repair, andmem-
brane trafﬁcking. Moreover, K63-linked polyubiquitinylation may also
serve as a marker for autophagy, although this proposal remains under
debate.
Ubiquitin is encoded by two distinct types of genes consisting of
mono- and poly-ubiquitin genes. The numbers of poly-ubiquitin
genes and their degree of tandem ubiquitin polymer differ by species.
Surprisingly, in what appears to be a universal feature of eukaryotic
species examined to date, at least two monoubiquitin genes are fused
with ribosomal protein genes. The precise biological signiﬁcance of
this fusion of two proteins with apparently opposite functions remains
unknown. In yeast, the polyubiquitin gene is indispensable under ther-
mal stress, but not under normal growth conditions [9]. In other words,the free ubiquitin levels are adequate under normal conditions, but sup-
plies must be rapidly increased for substrate conjugation under stress
conditions. As excess ubiquitin levels are harmful, ubiquitin homeosta-
sis is tightly controlled. In yeast, it has been shown that a balance is
maintained between a deubiquitinylating enzyme and its inhibitor
[10]. In mice, ubiquitin is encoded by two constitutively expressed
monoubiquitin (Uba) genes and two polyubiquitin genes, Ubb and
Ubc, that are stress inducible. Whereas targeted disruption of Ubb re-
sults inmale and female infertility due to the failure of meiotic progres-
sion [11], Ubc-deﬁcient mice die in utero between embryonic days 12.5
and 14.5, stressing the importance of homeostatic cellular ubiquitin
levels [12].
In the late 1980s, ubiquitin was found to be a component of paired
helical ﬁlaments (tau proteins) in Alzheimer's disease (AD) [13]. It re-
mains true that an abnormal enrichment of ubiquitin in an inclusion
body is a hallmark of various neurodegenerative disorders. The major
molecules associated with various diseases include α-synuclein with
Parkinson's disease (PD) and Lewy body dementia, polyglutamine
tracts with Huntington's disease, and TDP-43 (TAR-DNA binding
protein of 43 kDa) with frontotemporal lobar degeneration (FTLD)
and amyotrophic lateral sclerosis (ALS) [14]. To date, the signiﬁcance
of ﬁnding ubiquitin and/or ubiquitin polymer(s) in inclusion bodies
remains to be determined. Nonetheless, there are numerous clinical
reports demonstrating that ubiquitin is a diagnostic feature of most
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teristics of ubiquitin (i.e., number and/or species of polymer chain) in
the inclusion bodies of a variety of diseases remains unknown, a num-
ber of other details of the ubiquitin–proteasome system (UPS) and/or
autophagy in these neurodegenerative disorders have been worked
out. Indeed, emerging evidence implies that both UPS and autophagy
dysfunctions would lead to an accumulation of polyubiquitinylated
proteins, concomitant aggregation into inclusion bodies, and ultimate
neural cell death.
In addition, it has beenproposed that aggregated/misfoldedproteins
are speciﬁcally delivered to inclusion bodies by dynein-dependent
retrograde transport on microtubules to the centrosome, and that this
pericentrosomal cytoplasmic structure is called an aggresome [15].
Interestingly, the aggregated proteins are ubiquitinylated. Therefore, it
is likely that misfolded proteins accumulate in aggresomes when the
capacity of the intracellular protein degradationmachinery is exceeded.
However, the exact relationship between the aggresomes and the inclu-
sion bodies of a variety of diseases still remains to be determined.
3. Proteasome and neurodegeneration
3.1. Basic mechanisms of the proteasome
The 26S proteasome is a sophisticated 2.5-MDa complex containing
a catalytic core particle (CP, alias the 20S proteasome) and two terminal
19S regulatory particles (RP), which associate with both termini of
the central CP in opposite orientations [16–18]. The CP forms a
barrel-shaped particle of ~730 kDa consisting of four heptameric
rings, which result from the axial stacking of two outer α-rings and
two inner β-rings. These two rings are comprised of seven structur-
ally related α and β subunits, positioned in an α1–7β1–7β1–7α1–7
orientation. The CP contains three β-type subunits of inner β-rings
that contain catalytically active threonine residues at their N termini
and show N-terminal nucleophile (Ntn) hydrolase activity that cleaves
peptide bonds. The β1, β2, and β5 subunits are associated with
caspase-like, trypsin-like, and chymotrypsin-like activities, respectively,
that cleave peptide bonds at post-acidic, -basic, and -hydrophobic
amino-acid residues, respectively. Two pairs of these three active sites
reside within a chamber formed by the two abutting β-rings facing
the interior. The crystal structures of the CP reveal that the center of
the α-ring is almost completely closed, preventing substrate proteins
frompenetrating into the inner cavity of theβ-ringwhere theproteolyt-
ically active sites are located [19,20]. Indeed, the N-termini of the α
subunits form a physical barrier that prevents substrate protein(s)
from accessing the active sites in the β-ring, indicating that the CP is
latent in cells. Thus, a substrate is able to access the active sites only
after passing through a narrow opening in the closed gate at the center
of the α-rings.
The RP consists of a set of distinct integral subunits that can be
subclassiﬁed into two groups: a regulatory particle of six triple-ATPase
(Rpt) subunits and a regulatory particle of thirteen non-ATPase (Rpn)
subunits. A pair of symmetrically disposed RPs of ~930 kDa is attached
to both ends of the central CP at opposite orientations, forming the
so-called 26S holo-proteasome as the likely functional unit. The RP rec-
ognizes polyubiquitinylated proteins, deubiquitinylates them in order
to recycle the ubiquitin moieties, and then unfolds and translocates
the target proteins into the interior of the CP for destruction. Moreover,
the RP is also involved in opening theα-ring in the closed gate of the CP.
Thus, the RP essentially contributes to the four critical steps that occur
prior to the destruction of target proteins by the CP.
Intriguingly, a recent single particle analysis using cryo-EM revealed
that two ubiquitin receptors, Rpn10 and Rpn13, are located at a distant
site on the apical part of the RP complex near the periphery [21]. This
orientation is rational because both of these subunits serve as ubiquitin
(Ub) receptors; Rpn10 and Rpn13 collaboratively function as integral
ubiquitin receptors that efﬁciently trap substrateswith at least 4 ubiquitinpolymer chains, required for the initial stage of degradation. Very re-
cently, several groups independently delineated the complete subunit
architecture of the RP, and provided insight into the sequence of events
prior to the degradation of polyubiquitinylated substrates [22–25]. Ob-
viously, anothermajor function of the RP is to deubiquitinylate captured
substrates, a process in which the metalloisopeptidase, Rpn11, helps to
recycle the ubiquitin. Importantly, the Rpn11 deubiquitinylating en-
zyme (DUB) cleaves the polyubiquitin chain at a site proximal to the
substrate, coupled with substrate degradation. Rpn11 was found to be
located near the substrate entry position in the ATPase ring, elucidating
how the polyubiquitin chain is cleaved just before the substrate is incor-
porated into the Rpt complex channel. It is interesting that the other
two DUBs, Uch37 and USP14/UBP6, are physically associated with the
RP via the Rpn13 andRpn1 subunits, respectively, but their roles remain
enigmatic though they cleave ubiquitin distal to the substrate. TheATPase
ring is composed of six homologous AAA-ATPase subunits (Rpt1–Rpt6)
forming a crown-like shape. The ATPase ring serves the following three
functions [26]: 1) promotes substrate unfolding after the Rpt ring pulls
substrates into the central pore; 2) opens the channel in the closed
α-ring; and 3) translocates the substrates into the CP, thus ensuring
their destruction. In this mechanism, it is worth noting that the energy
generated by the Rpt ring has sufﬁcient force to promote the unfolding
of substrate structure domains. ATP is only used to unfold the target
proteins, but is not used to drive any other processes mediated by the
RP or the net proteolytic functions of the CP.
3.2. Neurodegeneration and aging
In general, animalmodels of neurodegenerative disorders are useful
to study disease-causingmechanisms andpharmacologic interventions.
A decade ago, to demonstrate the idea that proteasomal impairment
causes neurodegeneration, McNaught's group reported the establish-
ment of an animal model for PD using proteasome inhibitors, such as
lactacystin, epoxomicin, and PSI (Z-Ile-Glu(OtBu)-Ala-Leu-CHO) [27].
When adult ratswere treatedwith proteasome inhibitors, they developed
progressive characteristics of Parkinsonism, including bradykinesia, rigid-
ity and tremor, and dopaminergic cell death in the substantia nigra pars
compacta. The behavioral abnormalities were alleviated following treat-
ment with a dopamine agonist, and intracytoplasmic α-synuclein- and
ubiquitin-containing inclusions resembling Lewy bodies were observed
within the degenerating neurons, supporting the validity of this PD rat
model and causing great excitement in the PD community. Unfortunately,
however, this animal model subsequently became controversial because
some groups could only partially replicate previous ﬁndings reported by
McNaught and colleagues, while several other laboratories could not
reproduce the studies, indicating that systemic proteasome inhibition is
not a reliable PDmodel [reviewed in 28 and see references therein]. How-
ever, proteasome inhibitor studies are still conducted today, underscoring
the imperative role of the proteasome in neurodegeneration.
As an alternative approach to using proteasome inhibitors to un-
cover the in vivo role of the proteasome, mutant mice deﬁcient in var-
ious proteasomal genes have been generated. However, the ablation
of most proteasomal genes leads to embryonic lethality. Exceptions
include the immune-related proteasomal subunits, for example, the
triple deletion of three immunosubunits, β1i, β2i, and β5i [29], and
the deletion of the thymoproteasome subunit β5t [30]. Accordingly,
the establishment of a conditional knockout (cKO) mouse is necessary;
John Mayer's group made the ﬁrst cKO mouse of the proteasomal
ATPase subunit Rpt2/Psmc1 using the Cre/loxP system (Psmc1ﬂ/ﬂ)
[31]. In this model, Rpt2 could be speciﬁcally inactivated in dopaminer-
gic neurons within the substantia nigra. The speciﬁc impairment of
proteasomal activity in neurons of the nigrostriatal pathway led to
intraneuronal ubiquitin- andα-synuclein-positive Lewy-like inclusions
and extensive neurodegeneration. The authors claimed that the ob-
served Lewy-like inclusions resembled human pale bodies, which are
thought to be the early Lewy body form observed in patients with PD.
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result in neurodegeneration and Lewy-like inclusions resembling
human PD, providing direct evidence for the involvement of neuronal
proteasomal dysfunction in PD pathology. Furthermore, mice heterozy-
gous for Psmc1(+/−) functionwere neuropathologically and biochem-
ically indistinguishable from wild-type mice. Thus it is plausible that
defective function of the proteasome may contribute to the pathology
of PD. Interestingly, an age-related accumulation of intraneuronal lysine
48-speciﬁc polyubiquitin-positive granular staining was found in the
wild-type and heterozygous Psmc1(+/−) mouse brain, although both
mice were neuropathologically and biochemically indistinguishable
each other [32].
In another recent example, cKO mice in which another ATPase
subunit of the 26S proteasome, Rpt3/Psmc4, was deleted in a motor
neuron-speciﬁc manner revealed locomotor dysfunction accompanied
by progressive motor neuron loss and gliosis [33]. Moreover, diverse
amyotrophic lateral sclerosis (ALS)-linked proteins, including TDP-43,
fused in sarcoma (FUS), ubiquilin 2, and optineurin, were mislocalized
or accumulated in motor neurons, together with other typical ALS hall-
marks such as basophilic inclusion bodies, emphasizing the role of the
proteasome to maintain motor neuron homeostasis. Taken together,
these two genetic analyses in mice indicate that the proteasome has a
tight causal link to neurodegenerative diseases in general.
It is a widely accepted concept that age is a major risk factor for
sporadic and age-related neurodegenerative diseases. However, the
links between age-dependent proteotoxicity and cellular protein deg-
radation systems, e.g., the proteasome, remain poorly understood
because of the difﬁculty of evaluating proteasome functions in vivo.
Several synthetic peptide substrates with ﬂuorescence probes are
used to assay proteasomal activity in vitro; however, the resulting
data are presumably not directly related to the in vivo situation.
Recently, a genetic gain-of-function screen in the fruit ﬂy revealed
that 26S proteasomal activity and abundance attenuate with age,
and that this loss of activity is associated with the impaired assembly
of the CP and RP into the 26S proteasome [34]. In fact, Rpn11, which
encodes a deubiquitinylating subunit of the RP that recycles ubiquitin
tags from the target proteins, was identiﬁed as a suppressor of expand-
ed polyglutamine-induced progressive neurodegeneration. Intriguingly
Rpn11 overexpression suppressed the age-related reduction of the 26S
proteasomal activity, resulting in the extension of ﬂy lifespans and the
suppression of age-dependent accumulation of ubiquitinylated proteins.
By contrast, Rpn11 loss of function led to the early onset of reduced 26S
proteasomal activity and the premature age-dependent accumulation of
ubiquitinylated proteins. Rpn11 deﬁciency also caused a shorter lifespan
and an enhanced neurodegenerative phenotype. These results suggest
that maintaining the 26S proteasome with age could extend lifespan
and suppress the age-related progression of neurodegenerative diseases.
In genetic analyses using Caenorhabditis elegans, it was reported
that Rpn6/rpn-6 of the proteasomal RP subunit determines longevity
under proteotoxic stress conditions [35]. The forced re-investment of
resources from the germ line to the soma in C. elegans results in an
elevated somatic proteasomal activity, the clearance of damaged
proteins, and increased longevity. Interestingly, this activity is associated
with the increased expression of Rpn6 by the FOXO transcription factor
DAF-16. The ectopic expression of Rpn6 is sufﬁcient to confer proteotoxic
stress resistance and extend lifespan, implying that Rpn6 is a candidate
to correct deﬁciencies in age-related protein homeostasis disorders. Re-
cently, itwas also reported that human embryonic stemcells (hESCs) ex-
hibit high proteasomal activity that is correlated with increased levels of
Rpn6 and a corresponding increased assembly of the 26S proteasome
[36]. Ectopic expression of Rpn6 is sufﬁcient to increase proteasomal
assembly and activity. FOXO4, known as an insulin/insulin-like growth
factor-I (IGF-I)-responsive transcription factor associated with long
lifespan in invertebrates, regulates proteasomal activity by modulating
the expression of Rpn6 in hESCs. Proteasomal inhibition in hESCs affects
the expression of pluripotency markers and the levels of speciﬁc germlayer markers. Taken together, these ﬁndings suggest a novel regulation
of proteostasis in hESCs that links longevity and stress resistance in in-
vertebrates to hESC function and identity. The molecular mechanism of
the Rpn6 subunit andwhy itwould be solely responsible for proteasomal
function are unknown. Intriguingly, the crystal structure of Rpn6 and its
integration into the cryo-EM density map of the 26S holocomplex reveal
that Rpn6 has a pivotal role in stabilizing an otherwise weak interaction
between the CP and the RP, functioning as amolecular clampholding the
core and regulatory subcomplexes together, a possible explanation for
the key role of Rpn6 in the homeostatic stability of the 26S proteasome
[37].
We obtained a similar age-related scenario by generating PAC1-
conditional knockout mice [38]. Previously, we identiﬁed a set of
proteasome-dedicated assembling chaperones that assist in the as-
sembly of the CP and the RP proteasomal complexes [39,40]. One of
them is the proteasomal assembly chaperone 1 (PAC1) that assists
in the formation of the α-ring of the CP complex. To elucidate the
biological signiﬁcance of PAC1-mediated proteasomal assembly in
vivo, we generated PAC1-null and PAC1-cKO mice. PAC1-null mice,
which systemically lacked functional PAC1, exhibited early embryonic
lethality with death around E6.0. This result indicated that efﬁcient
PAC1-mediated proteasome biogenesis is needed to develop beyond
the blastocyst stage, and thus is essential for mouse development. Sub-
sequently, wemademice in which PAC1was ablated only in the central
nervous system (CNS). These animals displayed a large decrease in the
levels of both 20S and 26S proteasomes, which resulted in the severe
impairment of CNS development. Taken together, the study clearly
demonstrated that PAC1 is essential for mammalian development,
both during rapid embryonic growth and during the explosive neuronal
cell proliferation after birth.
4. Autophagy and neurodegeneration
4.1. Basic mechanisms of autophagy
Autophagy is a bulk degradative-recycling system coupled with the
lysosome, which contains a large set of hydrolytic enzymes for all mac-
romolecules such as proteins, carbohydrates, lipids, and nucleic acids.
Themajor autophagic pathway is calledmacroautophagy (hereafter re-
ferred to simply as autophagy); however, there are othermechanistical-
ly different types of autophagy, subcategorized as microautophagy and
chaperone-mediated autophagy, whose physiological roles remain
mostly unknown [41]. On the other hand, starvation-induced adaptive
autophagy and basal or constitutive autophagies have functionally dis-
tinct roles, though they share the same molecular players, i.e., Atg
(autophagy-related gene) proteins [3,42]. The principal role of the for-
mer type is to supply nutrients to cells under energy crisis and is dra-
matically induced in response to various stimuli, including starvation
(nutritional step-down) and humoral/trophic factors (e.g., glucagon).
Indeed, in response to nutritional stress, an isolationmembrane appears
promptly in the cytosol, where it gradually elongates to sequestrate
large amounts of cytoplasmic constituents. Thus, autophagosomes
surround cytoplasmic components including organelles at random to
adapt for starvation. Subsequently, the edges of the membrane fuse to-
gether to form double-membrane structures termed autophagosomes.
An autophagosome rapidly fuses with the lysosome, and their contents,
together with the inner membrane, are degraded by a variety of lyso-
somal digestive hydrolases. Actually, autophagy-deﬁcientmice produce
fewer amino acids during the neonate starvation period and die within
1 day after birth [43]. Analogously, autophagy is essential for the preim-
plantation development of mouse embryos under circumstances leading
to energy deprivation [44]. Adaptive autophagy is generally characterized
as a non-selective process.
In addition to the importance of starvation-induced (i.e., adaptive)
autophagy, growing lines of evidence point to the importance of a
basal autophagy that is constitutively active at low levels even under
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cellular components and quality control of cytoplasmic materials in-
cluding organelles [41,42]. This type of autophagy is characterized as a
selective process, and is referred to by various means, depending on
the degradative target(s). For example, terms for the selective disposal
of excess and damaged organelles include mitophagy, pexophagy, and
reticulophagy; for the selective disposal of ribosomes, ribophagy; for
the selective removal of lipid droplets, macrolipophagy; for the selective
elimination of pathogens, xenophagy, and innate immunity; and, for the
selective clearance of aggregate-prone proteins, aggrephagy. In addition,
autophagy is responsible for the global turnover of long-lived, but not
short-lived, proteins, and for MHC class II presentation of endogenous
proteins (adaptive immunity). Recent studies have focused on themech-
anisms and pathophysiological roles of selective autophagy.
4.2. Neurodegeneration and aging
The brain appears to be a specially protected tissue where nutrients
(e.g., amino acids, glucose, and ketone bodies) are kept in constant sup-
ply at the expense of other organs, even under severe starvation condi-
tions. Consequently, autophagy does not need to operate in the brain in
response to nutritional stress, although this phenomenon is controver-
sial, because there is a report showing the induction of neural cell au-
tophagy by short-term fasting [45]. However, morphological analyses
revealed that the accumulation of numerous or irregularly-shaped au-
tophagic vacuoles is a common feature of many inherited neurodegen-
erative diseases [42]. Indeed, the accumulation of aggregated proteins
in the surviving neurons detected that postmortem is a pathological
hallmark of diseases like AD, Huntington's disease (HD), and PD. How-
ever, the physiological and pathological signiﬁcance of these inclusion
bodies remain under debate (see below).
To deﬁne experimentally the role of autophagy in the in vivo brain,
we generated a mouse conditionally deﬁcient in Atg7, an essential
gene for the induction of autophagy [46]. In these animals, autophagy
could be selectively inactivated in the CNS. Mice lacking Atg7 in the CNS
exhibited various behavioral defects, including abnormal limb-clasping
reﬂexes and a reduction in coordinated movement, and died within
28 weeks after birth. Histological analyses showed that Atg7-deﬁciency
was associated with neuronal loss in the cerebral and cerebellar cortices.
Indeed, the loss of speciﬁc neurons, e.g., pyramidal neurons in the ce-
rebral cortex and hippocampus, and Purkinje cells in the cerebellum,
was clearly observed. Unexpectedly, immunohistological analysis
using an anti-ubiquitin antibody revealed an abundant accumulation
of polyubiquitinylated proteins in the Atg7-deﬁcient neurons. The
polyubiquitinylated proteins appeared as inclusion bodies, whose
size and number increased with aging, but the Atg7-deﬁcient neurons
had functionally intact proteasomes, the loss of which would cause ab-
normal ubiquitin-mediated proteolysis. This ﬁnding provided the ﬁrst
direct evidence to show that ubiquitin is used by both the proteasomal
and the autophagy degradative pathways as a discriminating tag ﬂagging
proteins for selective elimination. At the same time, Hara et al. reported
that almost all of these phenotypes were observed in mice that had
neural-speciﬁc deﬁciencies in Atg5, another autophagy-essential gene
[47]. Thus, many of the critical phenotypes detected in neural-speciﬁc
autophagy-deﬁcientmice resemble those of patientswith neurodegener-
ative disorders. Considered together, these studies stress the importance
of autophagy in neurodegeneration by demonstrating that suppressing
autophagy through the genetic deletion of Atg7 or Atg5 in the CNS causes
neurodegenerative disease in mice.
Furthermore, the speciﬁc ablation of Atg7 in Purkinje cells initially
causes cell-autonomous, progressive dystrophy (manifested by axo-
nal swellings) and degeneration of axon terminals, highlighting the
indispensable role of autophagy in neurodegeneration followed by
cell-autonomous Purkinje cell death and mouse behavioral deﬁcits
[48]. However, whereas the motor neuron-speciﬁc knockout of Rpt3,
which impacts the proteasome, led to severe malfunction, surprisingly,the motor neuron-speciﬁc knockout of Atg7, which impacts autophagy,
resulted in only subtle cytosolic accumulation of ubiquitin and p62,
with no TDP-43 or FUS pathologies or motor dysfunctions [33]. These
data suggested that proteasomal degradation, not autophagy, funda-
mentally governs the development of ALS mimic neurodegenerative
disease at least under the experimental setting. This ﬁnding is in sharp
contrast to autophagy deﬁciency in Purkinje cells as mentioned above.
Accordingly, it is plausible that the contributions of proteasomal degra-
dation and autophagy to the homeostatic control of proteostasis differ
among individual neurons.
While accumulation of ubiquitinylated proteins and cell death was
noted in autophagy-deﬁcient neurons, the same phenotypes were not
observed in growing cells, e.g., mouse embryonic ﬁbroblasts (MEFs)
and astroglia, irrespective of autophagy deﬁciency. Thus, it seems
that autophagy is not required in rapidly dividing cells, at least with
respect to their proliferation [3]. These results might also reﬂect the
difference in autophagic activity among cell types. It is possible that
the cell division cycle results in a dilution of ubiquitinylated proteins
in autophagy-deﬁcient MEFs, thus preventing their accumulation. Ac-
cordingly, autophagy is critical to non-dividing quiescent cells, such
as neurons, but not to growing cells with adequate nutrient supplies.
Intriguingly, genetic studies in C. elegans have shown that some of
the autophagy-related genes are required for the lifespan extension
induced by the inhibition of insulin/IGF-like signaling and calorie restric-
tion, although not all autophagy-related genes are longevity-promoting.
Likewise, autophagy is also required for lifespan extension induced
by the activation of sirtuins (higher eukaryote homologs of the
yeast NAD+-dependent deacetylase Sir2) and by silencing of TOR
[reviewed in 42,49 and see references therein]. Indeed, genetic studies
in C. elegans have shown that some of the autophagy-related genes
are required for the lifespan extension by the silencing of TOR and
the longevity-promoting effects are associated with caloric restric-
tion followed Sirtuin 1 (eukaryotic NAD+-dependent deacetylase)
activation and suppression of insulin/IGF-1 signaling. These results
indicate that autophagy is a common downstream effector in various
life-prolonging signaling pathways. Thinking mechanistically, how
much does autophagy contribute to the overall longevity effects?
How can autophagy prolong lifespan? Presumably, its role in removing
misfolded or aggregation-prone/unfolded proteins and damaged or-
ganelles (e.g., mitochondria) could be important. Moreover, autophagy
may reduce inﬂammatory cytokine secretion and spontaneous tumor
formation, which may also account for its longevity-promoting effects.
Additionally, normal and pathological aging are associated with a re-
duced autophagic potential. Thus, the age-dependent onset of neurode-
generative diseases most likely correlates with the age-dependent
decline of autophagic activity.5. The disposal of misfolded proteins and defective mitochondria
with respect to neurodegeneration
Over the last decade, studies on neurodegenerative diseases have
revealed a commonmechanismunderlying disease pathogenesis. Name-
ly, the adoption of abnormal conformations by certain proteins leads to
the formation of misfolded protein oligomers, which subsequently de-
velop into large protein aggregates. Then, the intracytoplasmic protein
aggregates entangle other denatured proteins and lipids to form
disease-speciﬁc inclusion bodies [2,42]. However, the mechanisms
underlying inclusion body formation in neurons are vague, and little
is known about the pathophysiological signiﬁcance (Fig. 2). The
landmark molecule in this context is p62, which harbors various
protein-interacting domains, such as the N-terminal self-oligomerizing
domain and the C-terminal ubiquitin-binding domain (UBA). p62 also
interacts with LC3 (via LRS, LC3-recognition sequence), Keap1, and
various signal transduction proteins, including TRAF6 and aPKC [50].
Quite interestingly, p62 is degraded via autophagy and is often used as
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Fig. 2. A controlling model for proteostasis in eukaryotic cells. Note that p62 is involved in the formation of protein aggregation caused by the loss of proteasomal and autophagic
degradations. For details, see text.
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report that p62 is also degraded by the proteasome [52].
Of morphological and pathological interest is the observation that
most ubiquitin-containing inclusion bodies clearly stainwith an anti-p62
antibody; thus, p62 is also known as sequestosome 1 (SQSTM1). The
pivotal role of p62 in the formation of protein aggregates has been
conﬁrmed using a p62-null mouse model. The genetic ablation of p62
suppressed the appearance of ubiquitin-positive protein aggregates in
neurons with impaired autophagy, indicating that p62 plays an impor-
tant role in inclusion body formation [51] (Fig. 2). These results imply
that polyubiquitinylated proteins might be selectively sequestered
into autophagosomes in part via p62 [42,51]. Thus, our results indicate
that autophagy serves to increase the supply of amino acids under
nutrient-poor conditions, and to clear away damaged proteins under
nutrient-rich conditions. A number of neuronal pathologists have re-
vealed that protein aggregation (as a dynamic process), especially olig-
omeric intermediates, is a mediator of toxicity. However, it is currently
claimed that the formation of “large” aggregates may reduce this
toxicity by virtue of the aggregates having lower surface area to vol-
ume ratios and thereby being less “reactive”. Whether the formation
of inclusion bodies in neurons is protective or toxic is under debate,
although emerging evidence suggests that protein aggregation can be a
protective mechanism (Fig. 2).
As mentioned above, the 26S proteasome has two integral ubiquitin
receptors, Rpn10 and Rpn13,which recognize and trap polyubiquitylated
proteins directly. In addition to the intrinsic ubiquitin receptors,
there are many shuttling factors, functioning as extrinsic ubiquitin
receptors, such as the UBL (ubiquitin-like)-UBA (ubiquitin-associated)
domain-containing proteins (e.g., Rad23, Dsk2, and Ddi1) and p62,
which can recruit indirectly many substrate proteins to the 26S
proteasome for destruction [1] (Fig. 2). Of them, p62 is a unique pro-
tein that serves as an adaptor of autophagy and is also responsible for
inclusion body formation by the impairment of autophagy. It is well
known that proteasome dysfunction can also cause the accumulation
of ubiquitin-positive inclusion bodies, but the mechanism(s) of ag-
gregation is poorly understood. It is interesting to question whether
p62 is involved in the aggregate formation evoked by proteasomal
deﬁciency. In this regard, using multiple strains of mice carrying
targeted genetic deletions, we recently obtained genetic evidence
that p62 regulates the formation of protein aggregates caused by deﬁ-
ciencies of the 26S proteasome (Kageyama et al., unpublished results),
indicating the generalized principal role of p62 in protein aggregation
(Fig. 2).However, to our surprise, the additional loss of p62 had little effect on
neuronal degeneration caused by autophagy-deﬁciency [51]. Nonethe-
less, protein aggregation in neurons lacking both Atg7 and p62 was
prevented, suggesting that the formation of an inclusion body itself
does not induce neuronal vulnerability. So why do autophagy-deﬁcient
mice develop neurodegeneration? In-depth morphological analyses of
autophagy-deﬁcient neurons revealed abnormalities in various organ-
elles, primarily mitochondria, whose autophagic elimination is termed
mitophagy. Considering that autophagy serves to remove mitochondria
and that malfunctioning mitochondria are tightly linked to cell death,
the excess accumulation of abnormalmitochondria is likely to be another
key factor in neuronal death due to the loss of autophagy.
Recently, the underlying mechanisms of mitophagy have been in-
vestigated, with particular emphasis on its relationship to Parkinson's
disease (PD), a neurodegenerative disorder associated with the pro-
gressive loss of dopaminergic neurons of the substantia nigra pars
compacta of the basal ganglia and locus coeruleus [53]. To date, in-
creasing evidence has revealed that mitochondrial failure and the
generation of reactive oxygen species (ROS), a by-product of ATP syn-
thesis in the mitochondrial respiratory chain, is tightly linked to the
cause of PD [54]. In this scenario, two key molecules, the causative
gene products of the two types of autosomal recessive early-onset famil-
ial PDs, play a central role. One is Parkin, a ubiquitin–protein ligase E3
[55,56], and the other is PINK1, a mitochondrial-targeted Ser/Thr kinase
[57]. The mechanisms through which the dysfunction of PINK1 and/or
Parkin causes PD have only recently become clear: Parkin-mediated
ubiquitinylation and PINK1 phosphorylation are key events in disease
pathogenesis. First, PINK1 monitors mitochondrial membrane potential
(integrity) and recruits and activates cytosolic parkin to depolarized mi-
tochondria [58–62]. Next, Parkin ubiquitinylated mitochondrial outer
membrane protein(s), thus inducing clearance by proteasomal degrada-
tion and/or mitophagy [53]. Speciﬁcally, PINK1 monitors depolarized/
damaged mitochondria in two elegant ways. In normal cells bearing
healthy mitochondria with a high membrane potential (ΔΨm), newly
synthesized PINK1 is rapidly degraded by a uniquemechanism consisting
of ΔΨm-dependent import through the TOM translocator of the outer
membrane into the TIM translocator in the inner membrane where the
PARL processing protease is located [63]. PINK1 is ﬁrst cleaved by PARL,
and then is exhaustively degraded by the 26S proteasome that is attached
to the outer mitochondrial membrane. Accordingly, PINK1 is barely de-
tectable in healthy mitochondria. On the other hand, loss of ΔΨm causes
the accumulation of PINK1, which is no longer imported into mitochon-
dria and so avoids PARL-mediated proteolysis [64]. Moreover, the
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rylation at Ser228 and Ser402 in a low ΔΨm-dependent manner [65].
Thus, PINK1 is regulated quantitatively andqualitatively bymitochondrial
membrane integrity. Activated PINK1 on damaged mitochondria recruits
cytosolic Parkin to the depolarized organelle. Interestingly, cytosolic
Parkin exists in a latent form whose activation is mediated in part
by the phosphorylation of its N-terminal Ser65 residue by activated
PINK1 [66], and is simultaneously recruited to the outer mitochondrial
membrane following full activation. Parkin, whose domains consist
of N-terminal UBL, RING0, RING1, IBR, and C-terminal RING2, is a
RING-IBR-RING-type ubiquitin-protein ligase (E3), functionally deﬁned
as a HECT- and RING-type hybrid E3 enzyme [67], i.e., RING1 binds
E2-ubiquitin and transfers it to RING2, which forms a thioester linkage
with ubiquitin, in aΔΨm-dependent fashion [67, Iguchi et al., to be pub-
lished]. Activated Parkin strongly polyubiquitinylated a set of outer
membrane proteins in a K48- and K63-linked polyubiquitin fashion,
the signal for proteasomal shredding and/or clearance by autophagy
(mitophagy) [53]. Finally, PINK1 accumulation by the decrease of and
subsequent recruitment of Parkin tomitochondria is etiologically impor-
tant because it was largely impeded by PD-linked mutations of PINK1 or
Parkin. Our results, together with reports by other groups, strongly sug-
gest that recessive familial PD is caused by dysfunctional quality control
for clearing depolarized mitochondria. At the present, we do not know
whether the aforementioned pathogenicmechanisms of recessive famil-
ial PD can be generalized to the prevalent sporadic PD. However, the
clinical symptoms of recessive familial PD caused by dysfunction of
PINK1 or Parkin resemble that of idiopathic PD, with the exception of
early-onset pathogenesis, and thus it is plausible that there is a common
pathogenic mechanism. Accordingly, we believe that our results provide
solid insights into the molecular mechanisms of PD pathogenesis, not
only for familial forms, but also for the major sporadic form of PD.
6. Concluding remarks
As depicted in Fig. 1, both proteasomal degradation and autophagy
perform a remarkable array of physiologically important cellular tasks,
and consequently their functional loss may lead to various pathological
situations. In this review, we have discussed the interplay between
proteostasis and neurodegeneration, focusing on proteasomal degrada-
tion and autophagy, both of which display age-dependent decreases in
activities and association with neurodegenerative diseases (see a
model depicted in Fig. 2). It is generally accepted that deﬁcits of the
proteasome are linked to various neurodegenerative disorders accompa-
nied by protein precipitation. While the proteasome fails to degrade
large protein aggregates, drug-induced activation of autophagy can ef-
fectively remove them [68], indicating that autophagy signiﬁcantly con-
tributes to the clearance of aggregate-prone proteins independent of the
proteasome. Unless the abundance of aggregates surpasses the clearance
capacity of theproteasome or autophagy, the activation of thosemachin-
eries by pharmaceutical agents could be effective in preventing disease
progression. For example, it is known that rapamycin, which induces au-
tophagy, has such an effect. However, while inhibitors are relatively easy
to ﬁnd, activators are harder to come by, particularly with respect to the
proteasome. Intriguingly, treating cultured cells with a small molecule
inhibitor of USP14, a proteasome-associated deubiquitinylating enzyme,
enhanced the degradation of several proteasomal substrates that have
been implicated in neurodegenerative disease [69]. Enhancement of
proteasomal activity through inhibition of USP14 may offer a strategy
to reduce the levels of aberrant proteins in cells under proteotoxic stress.
Accordingly, activators of the proteasome and/or autophagymay help to
design new strategies for the prevention of neurodegenerative diseases.
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